• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, February 7, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Chemicals hitch a ride onto new protein for better compounds

Bioengineer by Bioengineer
February 9, 2017
in Science News
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: Shixian Lin/Berkeley Lab

Chemists have developed a powerful new method of selectively linking chemicals to proteins, a major advance in the manipulation of biomolecules that could transform the way drugs are developed, proteins are probed, and molecules are tracked and imaged.

The new technique, called redox activated chemical tagging (ReACT), is described in the Feb. 10 issue of the journal Science. Developed at the Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab), it could fundamentally change the process of bioconjugation, the process by which chemicals and tags are attached to biomolecules, particularly proteins.

"We've essentially invented a new type of chemical Swiss army knife for proteins, the first that can be used for the essential and naturally occurring amino acid methionine," said study principal investigator Christopher Chang. "This ReACT method can be incorporated into a variety of different tools depending on what you need it to do. You can mix-and-match different reagents for a variety of applications."

Chang and fellow Berkeley Lab faculty scientist F. Dean Toste led this work as part of the Catalysis Program at Berkeley Lab's Chemical Sciences Division. Chang is also a Howard Hughes Medical Institute Investigator.

Hitching a ride onto a new protein

Toste compared the process of bioconjugation to hitching cargo onto the back of a pickup truck.

"That cargo can be used for many purposes," he said. "It can deliver drugs to cancerous cells, or it can be used as a tracking device to monitor the truck's movements. We can even modify the truck and change it to an ambulance. This change can be done in a number of ways, like rebuilding a truck or putting on a new hitch."

Bioconjugation traditionally relies upon the amino acid cysteine, which is highly reactive. Cysteine is often used as an attachment point for tags and chemical groups because it is one of two amino acids that contain sulfur, providing an anchor for acid-base chemistry and making it easy to modify.

But cysteine is often involved in the actual function of proteins, so "hitching cargo" to it creates instability and disrupts its natural function.

For this reason, people have been looking for ways to circumvent cysteine, and they naturally turned to methionine, the only other sulfur amino acid available. However, methionine has an extra carbon atom attached to its sulfur, which blocks most hitches. The researchers developed a new hitch using a process called oxidation-reduction chemistry that allows cargo to be attached to the methionine sulfur with this extra carbon still attached.

The potential of a chemical Swiss army knife

A key benefit to methionine is that it is a relatively rare amino acid, which allows researchers to selectively target it with fewer side effects and less impact on the biomolecule.

They put ReACT to the test by synthesizing an antibody-drug conjugate to highlight its applicability to biological therapeutics. They also identified the metabolic enzyme enolase as a potential therapeutic target for cancer, showing that the tool could help home in on new targets for drug discovery.

In the long term, the researchers say, this new bioconjugation tool could be used in:

  • Nanotechnology, where protein conjugation can help make nanomaterials compatible with air and water, reducing toxicity.
  • The creation of artificial enzymes that can be recycled, have better stability, and have improved activity and selectivity through chemical protein modification.
  • Synthetic biology, where it can be used to selectively make new proteins or augment the function of existing ones.

"This method could also add to the functionality of living organisms by directly modifying natural proteins to improve their stability and activity without making a genetically modified organism that relies on gene editing," said Chang. "It could have implications for the sustainable production of fuels, food, or medicines, as well as in bioremediation."

###

Co-lead authors of the study are Shixian Lin and Xiaoyu Yang, postdoctoral researchers at UC Berkeley. Both Chang and Toste are also professors of chemistry at UC Berkeley.

This work was supported by DOE's Office of Science. The National Institutes of Health also supported some of the pilot protein labeling studies that contributed to this work.

Lawrence Berkeley National Laboratory addresses the world's most urgent scientific challenges by advancing sustainable energy, protecting human health, creating new materials, and revealing the origin and fate of the universe. Founded in 1931, Berkeley Lab's scientific expertise has been recognized with 13 Nobel Prizes. The University of California manages Berkeley Lab for the U.S. Department of Energy's Office of Science. For more, visit http://www.lbl.gov.

DOE's Office of Science is the single largest supporter of basic research in the physical sciences in the United States, and is working to address some of the most pressing challenges of our time. For more information, please visit science.energy.gov.

Media Contact

Sarah Yang
[email protected]
510-486-4575
@BerkeleyLab

Home

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

Oxygen-Enhanced Dual-Section Microneedle Patch Improves Drug Delivery and Boosts Photodynamic and Anti-Inflammatory Treatment for Psoriasis

February 7, 2026

Scientists Identify SARS-CoV-2 PLpro and RIPK1 Inhibitors Showing Potent Synergistic Antiviral Effects in Mouse COVID-19 Model

February 7, 2026

Neg-Entropy: The Key Therapeutic Target for Chronic Diseases

February 7, 2026

Multidisciplinary Evidence-Based Guidelines for Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease

February 7, 2026
Please login to join discussion

POPULAR NEWS

  • Robotic Ureteral Reconstruction: A Novel Approach

    Robotic Ureteral Reconstruction: A Novel Approach

    82 shares
    Share 33 Tweet 21
  • Digital Privacy: Health Data Control in Incarceration

    63 shares
    Share 25 Tweet 16
  • Study Reveals Lipid Accumulation in ME/CFS Cells

    57 shares
    Share 23 Tweet 14
  • Breakthrough in RNA Research Accelerates Medical Innovations Timeline

    53 shares
    Share 21 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Oxygen-Enhanced Dual-Section Microneedle Patch Improves Drug Delivery and Boosts Photodynamic and Anti-Inflammatory Treatment for Psoriasis

Scientists Identify SARS-CoV-2 PLpro and RIPK1 Inhibitors Showing Potent Synergistic Antiviral Effects in Mouse COVID-19 Model

Neg-Entropy: The Key Therapeutic Target for Chronic Diseases

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 73 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.